Nineteen years of qualification
Audited Supplier
In This Store
Zhejiang Huahai Pharmaceuticals Co., Ltd.was initially founded in 1989, and the company's stock was successfully listed in Shanghai Stock Exchange in March, 2003.
Huahai Pharmaceuticals, a large scaled modern pharmaceutical group that integrates fomulations, APIs(Active Pharmaceutical Ingredients) and intermediates, is developing both domestic and international markets, and performing parallel development of science, industry and commerce. With a total asset of 1,900 million yuan, the company has 11branches (subsidiaries) in the United States, Shanghai, Hangzhou, and Linhai. It occupies an area of 800,000 square meters, and has a staff of 3400. The company is entitled as National Key Hi-tech Enterprise,National Pilot Enterprise of Innovation, and China's top 500 private enterprises, and possesses a "State Certified Enterprise Technology Center".
Huahai Pharmaceuticals is the largest supplier of pril products worldwide, with the annual production capacities of its dominating products "captopril" and "enalapril" both ranking first in the world. It is also the only manufacturer in the world that can realize commercial production of captopril, enalapril and lisinopril at the same time, enjoying the reputation of a "Pril Specialist". The pril drugs of the company boast absolute advantages in international markets in terms of production scale, product quality, technological skills and R&D.
The company's workshops of formulation are designed in strict compliance with the international cGMP standard, where the most advanced automatic pharmaceutical production equipment in the world was introduced. We are the first pharmaceutical company in China that has passed USA FDA approval.
Year of Establishment: 1989
Total Assets(USD): More than 99,999,999
Total Number of Staff: more than 1000
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Other Competitive Advantages:
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go
![[(2-methyl-1-propionylpropoxy)(4-phenylbutyl)phosphinoyl]acetic acid-cinchonidine](https://eimg.pharmasources.com/image/product/20200813/0e2276dd299837fe61224f06fa414fb4png!200)
![Ethyl 2-ethoxy-1-[(2'-cyanobiphenyl-4-yl)-methyl]-1H- benzimidazole-7-carboxylate](https://eimg.pharmasources.com/image/product/20200813/99bc20bb622154814d573d5c138bfc06png!200)
![N-[(2'-cyano[1,1'biphenyl]-4-yl)methyl]-methyl ester L-valine monohydrochloride](https://eimg.pharmasources.com/image/product/20200813/c0efc32fba02c90d5a2935b68bc8753dpng!200)
![N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine N-carboxyanhydride](https://eimg.pharmasources.com/image/product/20200813/e7a2ff8abc6890b96486537cbcd97163png!200)
![N-[1-[(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine](https://eimg.pharmasources.com/image/product/20200813/e579849eb99ab7774fb7c60a5b0ab5dcpng!200)
![Methyl 2-ethoxy-1-[(2'-cyanobiphenyl-4-yl)-methyl]-1H- benzimidazole-7-carboxylate](https://eimg.pharmasources.com/image/product/20200813/c04de8a0d868a351f316d91833626f06png!200)
